Published in Blood on January 14, 2009
Plasmacytoid dendritic cells: recent progress and open questions. Annu Rev Immunol (2011) 3.32
Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation. J Exp Med (2011) 1.78
Absence of STAT1 in donor-derived plasmacytoid dendritic cells results in increased STAT3 and attenuates murine GVHD. Blood (2014) 1.44
Recipient plasmacytoid DCs are not required to prime allogeneic T-cell responses after BMT. Blood (2009) 1.43
Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. Blood (2009) 1.35
Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease. Nat Med (2011) 1.34
Human dendritic cell deficiency: the missing ID? Nat Rev Immunol (2011) 1.32
Acute graft-versus-host disease: new treatment strategies. Curr Opin Hematol (2009) 1.16
Complexity of dendritic cell subsets and their function in the host immune system. Immunology (2011) 1.11
Antigen-presenting cell-derived complement modulates graft-versus-host disease. J Clin Invest (2012) 1.09
Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases. J Clin Immunol (2009) 1.08
Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity. Blood (2012) 1.06
IFN-γ and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity. Blood (2011) 1.02
HDAC inhibition and graft versus host disease. Mol Med (2011) 1.02
Langerhans cells are not required for graft-versus-host disease. Blood (2010) 1.01
Profound depletion of host conventional dendritic cells, plasmacytoid dendritic cells, and B cells does not prevent graft-versus-host disease induction. J Immunol (2012) 0.95
Ikaros-Notch axis in host hematopoietic cells regulates experimental graft-versus-host disease. Blood (2011) 0.91
Plasmacytoid dendritic cells: no longer an enigma and now key to transplant tolerance? Am J Transplant (2013) 0.87
Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research. Oral Dis (2012) 0.87
Biology of graft-versus-host responses: recent insights. Biol Blood Marrow Transplant (2013) 0.86
Delta-like ligand 4 identifies a previously uncharacterized population of inflammatory dendritic cells that plays important roles in eliciting allogeneic T cell responses in mice. J Immunol (2013) 0.86
Plasmacytoid dendritic cells in tolerance. Methods Mol Biol (2011) 0.84
The Notch Ligand DLL4 Defines a Capability of Human Dendritic Cells in Regulating Th1 and Th17 Differentiation. J Immunol (2015) 0.82
Rapamycin has suppressive and stimulatory effects on human plasmacytoid dendritic cell functions. Clin Exp Immunol (2013) 0.81
Plasmacytoid dendritic cells in allogeneic hematopoietic cell transplantation: benefit or burden? Bone Marrow Transplant (2015) 0.78
Fibroblastic niches prime T cell alloimmunity through Delta-like Notch ligands. J Clin Invest (2017) 0.78
Serum miR-29a Is Upregulated in Acute Graft-versus-Host Disease and Activates Dendritic Cells through TLR Binding. J Immunol (2017) 0.77
Oral chronic graft-versus-host disease: analysis of dendritic cells subpopulations. An Bras Dermatol (2014) 0.76
Efficacy of azithromycin in preventing lethal graft-versus-host disease. Clin Exp Immunol (2013) 0.75
Disease severity and mortality can be independently regulated in a mouse model of experimental graft versus host disease. PLoS One (2015) 0.75
Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood (2005) 6.16
Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med (2011) 6.02
MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell (2004) 5.98
Origin of the lamina propria dendritic cell network. Immunity (2009) 5.95
Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell (2007) 5.94
Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol (2007) 5.21
The origin and development of nonlymphoid tissue CD103+ DCs. J Exp Med (2009) 4.79
Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science (2005) 4.75
Mouse development and cell proliferation in the absence of D-cyclins. Cell (2004) 4.69
Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet (2004) 4.45
Myeloid or lymphoid promiscuity as a critical step in hematopoietic lineage commitment. Dev Cell (2002) 4.37
Deciphering the transcriptional network of the dendritic cell lineage. Nat Immunol (2012) 4.17
Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J Exp Med (2011) 3.88
Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha. Immunity (2004) 3.84
Hematopoietic stem cells expressing the myeloid lysozyme gene retain long-term, multilineage repopulation potential. Immunity (2003) 3.59
C/EBPbeta is required for 'emergency' granulopoiesis. Nat Immunol (2006) 3.53
Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci U S A (2002) 3.50
Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J Clin Invest (2004) 3.47
Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol (2004) 3.38
Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood (2005) 3.32
Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med (2012) 3.17
Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. Science (2014) 3.13
The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res (2005) 3.11
Plasmacytoid dendritic cells activate lymphoid-specific genetic programs irrespective of their cellular origin. Immunity (2004) 3.09
Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF. Science (2007) 2.92
Myeloid lineage commitment from the hematopoietic stem cell. Immunity (2007) 2.76
Distinctive and indispensable roles of PU.1 in maintenance of hematopoietic stem cells and their differentiation. Blood (2005) 2.64
Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell (2011) 2.62
The order of expression of transcription factors directs hierarchical specification of hematopoietic lineages. Genes Dev (2006) 2.62
Safety of workers at the Fukushima Daiichi nuclear power plant. Lancet (2011) 2.60
Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res (2007) 2.59
Developmental checkpoints of the basophil/mast cell lineages in adult murine hematopoiesis. Proc Natl Acad Sci U S A (2005) 2.59
Reciprocal activation of GATA-1 and PU.1 marks initial specification of hematopoietic stem cells into myeloerythroid and myelolymphoid lineages. Cell Stem Cell (2007) 2.57
Sequential roles of Brg, the ATPase subunit of BAF chromatin remodeling complexes, in thymocyte development. Immunity (2003) 2.56
Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell (2005) 2.51
Slug, a highly conserved zinc finger transcriptional repressor, protects hematopoietic progenitor cells from radiation-induced apoptosis in vivo. Cancer Cell (2002) 2.48
Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Cancer Res (2007) 2.35
The Kruppel-like factor KLF4 is a critical regulator of monocyte differentiation. EMBO J (2007) 2.34
Graft-versus-host disease disrupts intestinal microbial ecology by inhibiting Paneth cell production of α-defensins. Blood (2012) 2.30
CD169⁺ macrophages provide a niche promoting erythropoiesis under homeostasis and stress. Nat Med (2013) 2.26
Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol (2004) 2.26
Nfil3/E4bp4 is required for the development and maturation of NK cells in vivo. J Exp Med (2009) 2.26
Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood (2011) 2.24
Myeloerythroid-restricted progenitors are sufficient to confer radioprotection and provide the majority of day 8 CFU-S. J Clin Invest (2002) 2.22
Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001. J Thorac Oncol (2015) 2.12
Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood (2004) 2.11
GATA-1 converts lymphoid and myelomonocytic progenitors into the megakaryocyte/erythrocyte lineages. Immunity (2003) 2.05
Cyclin A is redundant in fibroblasts but essential in hematopoietic and embryonic stem cells. Cell (2009) 2.05
GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells. Immunity (2012) 1.98
Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum (2008) 1.97
Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience. J Thorac Oncol (2010) 1.96
Potential autoregulation of transcription factor PU.1 by an upstream regulatory element. Mol Cell Biol (2005) 1.96
Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol (2004) 1.91
Fanconi anemia FANCG protein in mitigating radiation- and enzyme-induced DNA double-strand breaks by homologous recombination in vertebrate cells. Mol Cell Biol (2003) 1.84
Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1. Nat Genet (2005) 1.82
Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J (2005) 1.79
Antagonism of FOG-1 and GATA factors in fate choice for the mast cell lineage. J Exp Med (2008) 1.79
B cell activation regulates exosomal HLA production. Eur J Immunol (2008) 1.78
Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation. J Exp Med (2011) 1.78
Interplay of host microbiota, genetic perturbations, and inflammation promotes local development of intestinal neoplasms in mice. J Exp Med (2014) 1.76
Identification of eosinophil lineage-committed progenitors in the murine bone marrow. J Exp Med (2005) 1.76
Proapoptotic BID is required for myeloid homeostasis and tumor suppression. Genes Dev (2003) 1.70
Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status. Lung Cancer (2003) 1.67
Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology (2005) 1.66
Expression of BCR/ABL and BCL-2 in myeloid progenitors leads to myeloid leukemias. Proc Natl Acad Sci U S A (2003) 1.64
TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells. Cell Stem Cell (2010) 1.64
Non-B, non-T neoplasms with lymphoblast morphology: further clarification and classification. Am J Surg Pathol (2003) 1.63
Successful treatment of primary cardiac lymphoma by rituximab-CHOP and high-dose chemotherapy with autologous peripheral blood stem cell transplantation. Int J Hematol (2007) 1.63
Adrenergic nerves govern circadian leukocyte recruitment to tissues. Immunity (2012) 1.63
Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy. Cancer (2007) 1.62
Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development. Proc Natl Acad Sci U S A (2004) 1.60
Hematopoietic stem cell defects in mice with deficiency of Fancd2 or Usp1. Stem Cells (2010) 1.60
FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood (2009) 1.59
Cross-presenting CD103+ dendritic cells are protected from influenza virus infection. J Clin Invest (2012) 1.57
The pathophysiology of acute graft-versus-host disease. Int J Hematol (2003) 1.55
Monocytic suppressive cells mediate cardiovascular transplantation tolerance in mice. J Clin Invest (2010) 1.55
Synergistic action of the microRNA-17 polycistron and Myc in aggressive cancer development. Cancer Sci (2007) 1.55
Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. Leuk Res (2010) 1.53
Cyclophosphamide-induced cardiomyopathy in a patient with seminoma and a history of mediastinal irradiation. Intern Med (2005) 1.49
Antimicrobial susceptibility and molecular epidemiological analysis of clinical strains of Pseudomonas aeruginosa. J Infect Chemother (2008) 1.48
Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res (2002) 1.48
Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal Nk/T-cell lymphoma, nasal type. Genes Chromosomes Cancer (2005) 1.47
Pretreatment prediction of interferon-alfa efficacy in chronic hepatitis C patients. Clin Gastroenterol Hepatol (2005) 1.47
Autoimmune neutropenia associated with multiple sclerosis. Intern Med (2003) 1.46
Role of CXCR3-induced donor T-cell migration in acute GVHD. Exp Hematol (2003) 1.46
Enforced granulocyte/macrophage colony-stimulating factor signals do not support lymphopoiesis, but instruct lymphoid to myelomonocytic lineage conversion. J Exp Med (2003) 1.45
Pivotal role of granulocyte colony-stimulating factor in the development of progenitors in the common myeloid pathway. Blood (2003) 1.44